Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02203825 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands
A Phase 1 study, sponsored by Celyad Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT02203825 is a Phase 1 study that has completed, run by Celyad Oncology. The registered enrollment target is 12 participants.
The verdict
NCT02203825, a Phase 1 study, has completed, sponsored by Celyad Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This Phase I clinical trial is evaluating chimeric-antigen receptor (CAR) T-cells (CM-CS1 T cells) which recognize NKG2D-ligands on the surface of cancer cells. This study evaluates the safety and feasibility of administering a single intravenous dose of CM-CS1 CAR T-cells to patients with AML, MDS-RAEB and Multiple Myeloma.
Interventions
- BIOLOGICAL CM-CS1 T-cell infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2015-03 |
| Est. Completion | 2018-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02203825
The ClinicalTrials.gov registry entry for NCT02203825 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celyad Oncology, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CM-CS1 T-cell infusion is the first listed.
NCT02203825 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02203825 about?
NCT02203825 is a clinical study titled "Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands". This Phase I clinical trial is evaluating chimeric-antigen receptor (CAR) T-cells (CM-CS1 T cells) which recognize NKG2D-ligands on the surface of cancer cells. This study evaluates the safety and feasibility of administering a single intravenous dose of CM-CS1 CAR T-cells to patients with AML, MDS-...
What is the current status of trial NCT02203825?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2015-03. Estimated completion is 2018-03.
What interventions are being tested in trial NCT02203825?
The interventions under investigation include: CM-CS1 T-cell infusion (BIOLOGICAL).
Who is sponsoring clinical trial NCT02203825?
This trial is sponsored by Celyad Oncology, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.